{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:58:38Z","timestamp":1790729918796,"version":"4.1.0"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2027,5,1]],"date-time":"2027-05-01T00:00:00Z","timestamp":1809129600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2027,5,1]],"date-time":"2027-05-01T00:00:00Z","timestamp":1809129600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T00:00:00Z","timestamp":1784160000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["valuehealthregionalissues.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health Regional Issues"],"published-print":{"date-parts":[[2027,5]]},"DOI":"10.1016\/j.vhri.2026.101691","type":"journal-article","created":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T03:57:16Z","timestamp":1789012636000},"page":"101691","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Cost-Effectiveness Analysis of Asciminib in Patients With Chronic Phase Chronic Myeloid Leukemia Previously Treated With 2 or More Tyrosine Kinase Inhibitors in Colombia"],"prefix":"10.1016","volume":"59","author":[{"given":"Mateo","family":"Ceballos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia","family":"Abello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pieralessandro","family":"Lasalvia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Jaramillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Alejandro","family":"Ospina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Prieto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Arias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.vhri.2026.101691_bib1","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.jmoldx.2013.04.007","article-title":"BCR-ABL1 RT-qPCR for monitoring the molecular response to tyrosine kinase inhibitors in chronic myeloid leukemia","volume":"15","author":"Press","year":"2013","journal-title":"J Mol Diagn"},{"issue":"9","key":"10.1016\/j.vhri.2026.101691_bib2","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1002\/ajh.26642","article-title":"Chronic myeloid leukemia: 2022 update on diagnosis, therapy, and monitoring","volume":"97","author":"Jabbour","year":"2022","journal-title":"Am J Hematol"},{"issue":"1","key":"10.1016\/j.vhri.2026.101691_bib3","doi-asserted-by":"crossref","first-page":"43","DOI":"10.6004\/jnccn.2024.0007","article-title":"Chronic myeloid leukemia, version 2.2024, NCCN clinical practice guidelines in oncology","volume":"22","author":"Shah","year":"2024","journal-title":"J Natl Compr Canc Netw"},{"issue":"14","key":"10.1016\/j.vhri.2026.101691_bib5","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","article-title":"Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia","volume":"344","author":"Druker","year":"2001","journal-title":"N Engl J Med"},{"issue":"Suppl 4","key":"10.1016\/j.vhri.2026.101691_bib6","doi-asserted-by":"crossref","first-page":"iv41","DOI":"10.1093\/annonc\/mdx219","article-title":"Chronic myeloid leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Hochhaus","year":"2017","journal-title":"Ann Oncol"},{"issue":"24","key":"10.1016\/j.vhri.2026.101691_bib7","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1200\/JCO.2015.66.2866","article-title":"Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population","volume":"34","author":"Bower","year":"2016","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.vhri.2026.101691_bib8","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1038\/leu.2016.5","article-title":"Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial","volume":"30","author":"Hochhaus","year":"2016","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.vhri.2026.101691_bib9","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1038\/s41375-022-01589-y","article-title":"Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: final results from the BFORE trial","volume":"36","author":"Br\u00fcmmendorf","year":"2022","journal-title":"Leukemia"},{"issue":"20","key":"10.1016\/j.vhri.2026.101691_bib10","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1200\/JCO.2015.64.8899","article-title":"Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-na\u00efve chronic myeloid leukemia patients trial","volume":"34","author":"Cortes","year":"2016","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.vhri.2026.101691_bib11","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1002\/ajh.24536","article-title":"Long-term Bosutinib for chronic phase chronic myeloid leukemia after failure of imatinib plus dasatinib and\/or nilotinib","volume":"91","author":"Cortes","year":"2016","journal-title":"Am J Hematol"},{"issue":"5","key":"10.1016\/j.vhri.2026.101691_bib12","doi-asserted-by":"crossref","first-page":"e290","DOI":"10.1016\/j.clml.2024.12.015","article-title":"Real world evidence from 2 decades of first-line TKI therapy in chronic myeloid leukemia (CML): insights from ACHO\u2019s RENEHOC registry","volume":"25","author":"Abello Polo","year":"2025","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.vhri.2026.101691_bib13","series-title":"Third-line tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia (CML) in Colombia: report from the RENEHOC investigators","author":"Abello","year":"2024"},{"issue":"4","key":"10.1016\/j.vhri.2026.101691_bib14","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","article-title":"European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia","volume":"34","author":"Hochhaus","year":"2020","journal-title":"Leukemia"},{"issue":"24","key":"10.1016\/j.vhri.2026.101691_bib15","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1056\/NEJMoa1902328","article-title":"Asciminib in chronic myeloid leukemia after ABL kinase inhibitor failure","volume":"381","author":"Hughes","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vhri.2026.101691_bib17","series-title":"Scemblix","year":"2022"},{"key":"10.1016\/j.vhri.2026.101691_bib20","series-title":"Manual para la elaboraci\u00f3n de evaluaciones econ\u00f3micas en salud","year":"2014"},{"issue":"3","key":"10.1016\/j.vhri.2026.101691_bib21","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1093\/heapol\/czab146","article-title":"Estimating cost-effectiveness thresholds under a managed healthcare system: experiences from Colombia","volume":"37","author":"Espinosa","year":"2022","journal-title":"Health Policy Plan"},{"issue":"21","key":"10.1016\/j.vhri.2026.101691_bib22","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1182\/blood.2020009984","article-title":"A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs Bosutinib in CML after 2 or more prior TKIs","volume":"138","author":"R\u00e9a","year":"2021","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.vhri.2026.101691_bib23","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s12185-024-03805-0","article-title":"Asciminib in patients with CML-CP previously treated with \u2265 2 tyrosine kinase inhibitors: 96-week results from the Japanese subgroup analysis of the ASCEMBL study","volume":"120","author":"Minami","year":"2024","journal-title":"Int J Hematol"},{"issue":"9","key":"10.1016\/j.vhri.2026.101691_bib24","doi-asserted-by":"crossref","first-page":"6247","DOI":"10.1007\/s00432-022-04562-5","article-title":"Matching-adjusted indirect comparison of asciminib versus other treatments in chronic-phase chronic myeloid leukemia after failure of two prior tyrosine kinase inhibitors","volume":"149","author":"Atallah","year":"2023","journal-title":"J Cancer Res Clin Oncol"},{"issue":"4","key":"10.1016\/j.vhri.2026.101691_bib25","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1182\/blood-2016-09-739086","article-title":"Ponatinib efficacy and safety in Philadelphia chromosome\u2013positive leukemia: final 5-year results of the phase 2 PACE trial","volume":"132","author":"Cortes","year":"2018","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.vhri.2026.101691_bib26","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1038\/leu.2010.110","article-title":"Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapy","volume":"24","author":"Giles","year":"2010","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.vhri.2026.101691_bib27","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1159\/000495335","article-title":"Responses to dasatinib as a second- and third-line tyrosine kinase inhibitor in chronic phase chronic myeloid leukaemia patients","volume":"142","author":"Tan","year":"2019","journal-title":"Acta Haematol"},{"issue":"5","key":"10.1016\/j.vhri.2026.101691_bib28","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1038\/s41375-023-01888-y","article-title":"Health-related quality of life of patients with resistant\/intolerant chronic phase chronic myeloid leukemia treated with asciminib or Bosutinib in the phase 3 ASCEMBL trial","volume":"37","author":"R\u00e9a","year":"2023","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.vhri.2026.101691_bib29","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/j.1524-4733.2009.00573.x","article-title":"A multinational study of health state preference values associated with chronic myelogenous leukemia","volume":"13","author":"Szabo","year":"2010","journal-title":"Value Health"},{"issue":"3","key":"10.1016\/j.vhri.2026.101691_bib31","doi-asserted-by":"crossref","first-page":"399","DOI":"10.3324\/haematol.2012.064337","article-title":"Outcome of 82 chronic myeloid leukemia patients treated with nilotinib or dasatinib after failure of two prior tyrosine kinase inhibitors","volume":"98","author":"Rossi","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.vhri.2026.101691_bib32","author":"Tatar"},{"issue":"3","key":"10.1016\/j.vhri.2026.101691_bib40","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/s41375-024-02159-0","article-title":"Dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trials","volume":"38","author":"Jabbour","year":"2024","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.vhri.2026.101691_bib41","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1002\/ajh.27443","article-title":"Chronic myeloid leukemia: 2025 update on diagnosis, therapy, and monitoring","volume":"99","author":"Jabbour","year":"2024","journal-title":"Am J Hematol"},{"issue":"5","key":"10.1016\/j.vhri.2026.101691_bib43","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.farma.2024.03.008","article-title":"Asciminib for third-line treatment of chronic myeloid leukemia: cost-effectiveness analysis based on treatment-free remission approach","volume":"48","author":"Garcia Molina","year":"2024","journal-title":"Farm Hosp"},{"issue":"3","key":"10.1016\/j.vhri.2026.101691_bib49","doi-asserted-by":"crossref","first-page":"336","DOI":"10.11144\/Javeriana.SC283.poca","article-title":"Patterns of chromosome abnormalities in a sample of Colombian patients with chronic myeloid leukemia","volume":"28","author":"Largo-Peralta","year":"2023","journal-title":"Univ Sci"}],"container-title":["Value in Health Regional Issues"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212109926001068?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212109926001068?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:19:35Z","timestamp":1790727575000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212109926001068"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2027,5]]},"references-count":31,"alternative-id":["S2212109926001068"],"URL":"https:\/\/doi.org\/10.1016\/j.vhri.2026.101691","relation":{},"ISSN":["2212-1099"],"issn-type":[{"value":"2212-1099","type":"print"}],"subject":[],"published":{"date-parts":[[2027,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost-Effectiveness Analysis of Asciminib in Patients With Chronic Phase Chronic Myeloid Leukemia Previously Treated With 2 or More Tyrosine Kinase Inhibitors in Colombia","name":"articletitle","label":"Article Title"},{"value":"Value in Health Regional Issues","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vhri.2026.101691","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of International Society for Pharmacoeconomics and Outcomes Research, Inc.","name":"copyright","label":"Copyright"}],"article-number":"101691"}}